Canaccord analyst Kyle Mikson raised the firm’s price target on Illumina (ILMN) to $130 from $112 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they see a key catalyst in 2026 for Illumina with its AXELIOS luanch with Roche Holdings.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $130 from $105 at JPMorgan
- Illumina price target raised to $110 from $100 at Barclays
- Illumina, MyOme announces collaboration, investment by Illumina into MyOme
- Illumina Completes $500M Notes Offering for Expansion
- Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS